These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27868145)

  • 21. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
    Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
    Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
    Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
    Noda S; Mizuno K; Adachi M
    J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R; Unnebrink K; Valdecantos WC
    J Drugs Dermatol; 2015 Aug; 14(8):864-8. PubMed ID: 26267731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis.
    Matsumoto A; Komine M; Karakawa M; Kishimoto M; Ohtsuki M
    J Dermatol; 2017 Feb; 44(2):202-204. PubMed ID: 27743397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure.
    Kusakari Y; Yamasaki K; Takahashi T; Tsuchiyama K; Shimada-Omori R; Nasu-Tamabuchi M; Aiba S
    J Dermatol; 2015 Jul; 42(7):727-30. PubMed ID: 25916786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
    Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
    Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
    Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
    J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.
    Chiricozzi A; Bianchi L; Zangrilli A; Bavetta M; Giunta A; Chimenti S; Saraceno R
    Eur J Dermatol; 2015; 25(1):64-9. PubMed ID: 25514606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
    Inzinger M; Wippel-Slupetzky K; Weger W; Richter L; Mlynek A; Fleischander B; Scheurecker C; Sandor N; Mairhofer D; Sator PG; Moser-Oberthaler S; Häring N; Viznerova P; Painsi C; Tanew A; Ponholzer P; Tatarski R; Brenner W; Stingl G; Salmhofer W; Rappersberger K; Klein G; Saxinger W; Auböck J; Kölli C; Trautinger F; Steiner A; Ratzinger G; Strohal R; Riedl E; Lange-Asschenfeldt B; Pehamberger H; Volc-Platzer B; Selhofer S; Legat FJ; Müllegger R; Reider N; Schmuth M; Hintner H; Hofer A; Gruber-Wackernagel A; Aberer W; Quehenberger F; Wolf P
    Acta Derm Venereol; 2016 Feb; 96(2):207-12. PubMed ID: 26271044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.
    Pina T; Armesto S; Lopez-Mejias R; Genre F; Ubilla B; Gonzalez-Lopez MA; Gonzalez-Vela MC; Corrales A; Blanco R; Garcia-Unzueta MT; Hernandez JL; Llorca J; Gonzalez-Gay MA
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1325-30. PubMed ID: 25353352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY; Chu TW; Cheng YP; Tsai TF
    PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis.
    Luber AJ; Tsui CL; Heinecke GM; Lebwohl MG; Levitt JO
    J Am Acad Dermatol; 2014 Mar; 70(3):525-32. PubMed ID: 24388425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.